Skip to main content

Table 3 Associations between PTPRO methylation and clinicopathological features of breast cancer

From: Aberrant PTPRO methylation in tumor tissues as a potential biomarker that predicts clinical outcomes in breast cancer patients

Characteristics No. PTPROmethylation
   Tumor tissue (%) χ2 Pvalue plasma (%) χ2 Pvalue
Total 98 53 (54)    33 (34)   
Age        
< 45 years 45 22 (49)    16 (36)   
≥ 45 years 53 31 (59) 0.903 0.417 17 (32) 0.132 0.716
Nodal involvement        
Negative 61 27 (44)    18 (30)   
Positive 37 26 (70) 6.273 0.014 15 (40) 0.935 0.334
Stage        
I/II 79 37 (47)    24 (30)   
III 19 16 (84) 8.616 0.004 9 (47) 1.979 0.159
Histological type        
Non-ductal 23 12 (52)    7 (30)   
Ductal 75 41 (55) 1.000 0.510 26 (35) 0.141 0.707
Tumour size        
≤20 mm 47 26 (55)    12 (26)   
>20 mm 51 27 (53) 0.056 0.842 21 (40) 2.234 0.135
Histological grade        
Well/mod diff. 60 27 (45)    18 (30)   
Poorly diff. 38 26 (68) 5.139 0.037 15 (40) 0.935 0.334
ER status        
Negative 24 16 (67)    10 (42)   
Positive 74 37 (50) 2.027 0.167 23 (31) 0.909 0.340
PR status        
Negative 29 20 (69)    10 (35)   
Positive 69 33 (48) 3.674 0.076 23 (33) 0.012 0.912
HER2 status        
Normal 51 19 (37)    12 (24)   
Amplified 47 34 (72) 12.124 0.001 21 (46) 5.570 0.018
TP53 status        
Normal 59 30 (51)    17 (29)   
Mutant 39 23 (59) 0.624 0.535 16 (41) 1.568 0.211
\